Last reviewed · How we verify
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer (Bullseye)
Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. In the last few years, several lutetium-177 (177Lu, β emitter) labeled PSMA ligands have been developed and are currently applied to treat metastatic castrate resistant prostate cancer patients. To date, there are no prospective randomized studies published using this treatment in the hormone sensitive setting or in oligometastatic prostate cancer. Therefore, this study we will evaluate the effect of 177Lu-PSMA in patients with hormone sensitive oligo-metastatic prostate cancer.
Details
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 58 |
| Start date | Mon Jul 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Prostate Cancer
Interventions
- 177Lu-PSMA-617
Countries
Netherlands, Cyprus